6.60

1.54% +0.10

After Hours: 6.60

Pasithea Therapeutics Corp (KTTA)

Overview News Price History Financials Discussions Forecast

Pasithea Therapeutics Corp stock is currently priced at $6.60, with a 24-hour trading volume of 449. It has seen a +1.54% increased in the last 24 hours and a -7.69% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $6.54 pivot point. If it approaches the $6.65 resistance level, significant changes may occur.

Previous Close:

$6.50

Open:

$6.6

24h Volume:

449

Market Cap:

$6.88M

Revenue:

Net Income/Loss:

$-15.96M

P/E Ratio:

-10.15

EPS:

-0.65

Net Cash Flow:

$-12.85M

1W Performance:

-14.06%

1M Performance:

-7.69%

6M Performance:

+2,028%

1Y Performance:

+1,841%

1D Range:

$6.60

52W Range:

$0.2627

$9.25

Pasithea Therapeutics Corp Stock (KTTA) Company Profile

Name

Pasithea Therapeutics Corp

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

702 514 4174

Address

1111 Lincoln Road, Suite 500, Miami Beach

Employee

Twitter

Next Earnings Date

2024-05-15

Latest SEC Filings

KTTA's Discussions on Twitter

Pasithea Therapeutics Corp Stock (KTTA) Latest News

Pasithea Therapeutics : Shareholder Meeting - Form 8-K - Marketscreener.com

Marketscreener.com

Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting - Yahoo Finance

Yahoo Finance

(KTTA) Technical Data - Stock Traders Daily

Stock Traders Daily

Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004 - GlobeNewswire

GlobeNewswire

Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients

GlobeNewswire Inc.

Pasithea conducts 1-for-20 reverse stock split, gets FDA okay for study (NASDAQ:KTTA) - Seeking Alpha

Seeking Alpha

Pasithea Therapeutics Corp Stock (KTTA) Financials Data

Pasithea Therapeutics Corp (KTTA) Net Income 2024

KTTA net income (TTM) was -$15.96 million for the quarter ending December 31, 2023, a -14.53% decrease year-over-year.

Pasithea Therapeutics Corp (KTTA) Cash Flow 2024

KTTA recorded a free cash flow (TTM) of -$12.85 million for the quarter ending December 31, 2023, a -7.05% decrease year-over-year.

Pasithea Therapeutics Corp (KTTA) Earnings per Share 2024

KTTA earnings per share (TTM) was -$13.01 for the quarter ending December 31, 2023, a -20.13% decline year-over-year.

Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida.